Kelly Paul Edward

Avg. Two Year Performance

13% Avg. Purchase Return
6% Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return15%73%63%72%13%
Purchase Success Rate2 of 32 of 32 of 32 of 31 of 3
Average Sale Return0%0%0%0%0%
Sale Success Rate0 of 30 of 30 of 30 of 30 of 3

Relmada Therapeutics, Inc.

Drugs » Drugs - Generic

Director:

Holdings: 212.29K shares

Sentiment

Insider Trading Sentiment: Accumulate

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--